Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905963 | 0.96 | ADORA3 (0.53) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL29651433 | 0.94 | LPAR1 (0.52) | — | |
| SCHEMBL9905968 | 0.91 | NR1I2 (0.43) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL29372509 | 0.90 | LPAR1 (0.55) | — | |
| SCHEMBL17482404 | 0.90 | LPAR1 (0.55) | — | |
| SCHEMBL9905967 | 0.88 | MGLL (0.45) | ALDH1A1 | |
| SCHEMBL471877 | 0.84 | ALDH1A1 (0.66) | ALDH1A1CYP3A4ALOX15TSHRHSD17B10 | |
| SCHEMBL17320970 | 0.82 | LPAR1 (0.62) | — | |
| SCHEMBL29651480 | 0.82 | LPAR1 (0.62) | — | |
| SCHEMBL17232174 | 0.82 | LPAR1 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925165-B2 | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof | SCF PHARMA INC. (CA) | 2018-03-27 | — | — | US | disclosed |
| US-9925165-B2 | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof | SCF PHARMA INC. (CA) | 2018-03-27 | — | — | US | disclosed |
| US-20170014369-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-20170014369-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-9480660-B2 | Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof | SCF PHARMA INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9480660-B2 | Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof | SCF PHARMA INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9233915-B2 | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof | SCF PHARMA INC. (CA) | 2016-01-12 | — | — | US | disclosed |
| US-9233915-B2 | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof | SCF PHARMA INC. (CA) | 2016-01-12 | — | — | US | disclosed |
| US-9101563-B2 | Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof | SCF PHARMA INC (CA) | 2015-08-11 | — | — | US | disclosed |
| US-9101563-B2 | Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof | SCF PHARMA INC (CA) | 2015-08-11 | — | — | US | disclosed |
| US-20100196496-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2010-08-05 | — | — | US | disclosed |
| US-20100196496-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2010-08-05 | — | — | US | disclosed |
| US-20100160261-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | SCF PHARMA INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160261-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | SCF PHARMA INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20090291102-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090292019-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090291102-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090292019-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| WO-2008113177-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008098375-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196496-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | MGLL, PNLIP, FASN | ALDH1A1 1033/4885CYP3A4 1541/4885ALOX15 17/4885 |
| US-20090292019-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | FASN, MGLL, FADS1 | ALDH1A1 695/4885CYP3A4 4044/4885ALOX15 34/4885 |
| US-20170014369-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | PPARG, PTGES, PTGIS | ALDH1A1 1476/4885CYP3A4 2829/4885ALOX15 13/4885 |
| US-20090291102-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | MGLL, PNLIP, FASN | ALDH1A1 1033/4885CYP3A4 1541/4885ALOX15 17/4885 |
| US-20100160261-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | FASN, MGLL, FADS1 | ALDH1A1 695/4885CYP3A4 4044/4885ALOX15 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.